论文部分内容阅读
编者按《继承免疫疗法治疗癌症的疗效有限,但有些病例则获得了令人鼓舞的成功。少数恶性黑色素瘤和肾细胞瘤患者对IL-2或IL-2加LAK 细胞治疗有效。其机制和疗效不同的原因不明。在本文中,Gior-gio Parmiani 提出,成功的继承疗法取决于宿主激活的抗肿瘤T 淋巴细胞的补充。这就解释了在抗黑色素病和肾细胞癌中肿瘤浸润淋巴细胞所起的较大作用。》实验表明,用肿瘤特异性T 细胞作继承免疫治疗可治愈荷瘤动物。除排斥它们自己的免疫原性恶性增生组织外,这些动物还产生了持久的全身免疫。这种免疫可能是由于供者免疫T 细胞长期持续存在的结果。另
The editors have limited efficacy in the treatment of cancer by inherited immunotherapy, but some cases have achieved encouraging success. A small number of patients with malignant melanoma and renal cell tumors are effective in treating IL-2 or IL-2 plus LAK cells. The reason for the difference in its mechanism and efficacy is unknown. In this article, Gior-gio Parmiani suggested that successful inheritance therapy depends on the complementation of host-activated antitumor T lymphocytes. This explains the greater role of tumor-infiltrating lymphocytes in anti-melanotic diseases and renal cell carcinoma. "Experiments have shown that tumor-specific T cells can be used to treat tumor-bearing animals using inherited immunotherapy. In addition to rejecting their own immunogenic malignant tissue, these animals also have a lasting systemic immunity. This immunity may be due to the long-term persistence of donor immune T cells. another